Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

More Growth Ahead For Farxiga From First-In-Class Kidney Disease Approval

Closing Down Jardiance’s Lead

Executive Summary

AstraZeneca’s SGLT2 inhibitor produced 50% growth in Q1, and its new chronic kidney disease approval will give it an edge over Lilly and Boehringer’s Jardiance.

You may also be interested in...



AstraZeneca’s Farxiga DELIVERs With Fresh Heart Failure Data

AstraZeneca's SGLT2 inhibitor Farxiga could soon get approval as an option for all heart failure patients following the success of the large Phase III DELIVER trial in people with preserved ejection fraction.

Boehringer Pharma Chief Confident Of Continued Success For Jardiance

Carinne Brouillon, head of the German major’s human pharma business unit, tells Scrip that Jardiance’s leadership in interconnected cardio-metabolic-renal diseases has been demonstrated and the product is set to keep rising as new indications come onboard.

After Jardiance Heart Failure Successes, BI And Lilly Focus On Kidney

Jardiance, the best-selling SGLT2 inhibitor, has AstraZeneca’s same-class rival Farxiga firmly in its sights in renal disease after showing such a level of efficacy that the 6,600-patient EMPA-KIDNEY study has been halted.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144294

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel